Serina Therapeutics, Inc. — Form SCHEDULE 13D/A
Filed July 22, 2026 · analyzed by the Ownership Agent
SCHEDULE 13D/A
— Neutral
significance 22/100
What the filing says
Juvenescence Ltd filed an amended Schedule 13D/A on July 22, 2026, regarding its beneficial ownership in Serina Therapeutics, Inc. The filing document itself contains no specific disclosure of amended ownership percentages, share counts, dollar amounts, or changes to previously reported beneficial ownership stakes. The original Schedule 13D and nature of the amendment are not detailed in this filing header.
Why this rating
Amendment to Schedule 13D is routine disclosure. Without specific ownership changes disclosed, cannot assess materiality to $21.8M company.
See more from July 22, 2026.
EDGAR·FLOW summarizes public SEC EDGAR filings with automated analysis. Materiality scores and stock-impact predictions are algorithmically generated and are not investment advice. Always verify against the source filing on SEC.gov.